| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000007946 |
| Receipt No. | R000009361 |
| Official scientific title of the study | Peginterferon(PEG-IFN) alfa-2a in chronic hepatitis B patients without nucleos(t)ide analogues (NA) treatment |
| Date of disclosure of the study information | 2012/05/14 |
| Last modified on | 2017/11/13 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Peginterferon(PEG-IFN) alfa-2a in chronic hepatitis B patients without nucleos(t)ide analogues (NA) treatment | |
| Title of the study (Brief title) | PEG-IFN for CH-B | |
| Region |
|
|
| Condition | ||
| Condition | Patients infected with hepatitis B virus | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To examine the safety and efficacy in peginterferon alfa-2a therapy in Japanese Chronic hepatitis B patients |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | HBV DNA and ALT levels at 24 week after stopping the treatment |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients were eligible if they met the following inclusion criteria: (i) infected with HBV alone, (ii) age =>20 years, (iii) diagnosed as chronic hepatitis B, (iv) WBC =>3000/mm3 , (v) neutrophils =>1500/mm3, (vi) platelets =>90000/mm3, (vii) hemoglobin => 12 g/dL, (viii) Doctors judged patient as appropriate person in this trial, (ix)HBV DNA-positive patients, (x)no or mild hepatic fibrosis, (xi) patient and his/her family underst and well this disease and treatment. | |||
| Key exclusion criteria | 1) Pregnancy
2) Severe liver diseases 3) Cirrhosis or hepatic failure such as chronic liver diseases, e.g. autoimmune hepatitis and alcoholic hepatitis 4) Severe other diseases 5) History of pneumonitis 6) Past-history of hypersensitivity against interferon or peginterferon, etc. 7) Severe mental disorders 8) Abnormal hematological exams 9) Past-history of hypersensitivity against vaccination, etc. 10) Under treatment of TJ-9 11) Doctor judged patient as inappropriate person in this trial |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Osamu Yokosuka, M.D. |
| Organization | Chiba University, Graduate School of Medicine |
| Division name | Department of Gastroenterology and Nephrology |
| Address | 1-8-1 Inohana, Chuo-ku, Chiba, Japan (260-8677) |
| TEL | 0432262086 |
| kandat-cib@umin.ac.jp | |
| Public contact | |
| Name of contact person | Tatsuo Kanda, M.D. |
| Organization | Chiba University, Graduate School of Medicine |
| Division name | Department of Gastroenterology and Nephrology |
| Address | 1-8-1 Inohana, Chuo-ku, Chiba, Japan (260-8677) |
| TEL | 0432262086 |
| Homepage URL | |
| kandat-cib@umin.ac.jp | |
| Sponsor | |
| Institute | Chiba University, Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Chiba University, Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | In future, we will perform the observation study. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009361 |